Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Aug;62(8):3146–3155. doi: 10.1128/iai.62.8.3146-3155.1994

Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

H K Johansen 1, F Espersen 1, S J Cryz Jr 1, H P Hougen 1, A Fomsgaard 1, J Rygaard 1, N Høiby 1
PMCID: PMC302939  PMID: 8039883

Abstract

Pseudomonas aeruginosa is the predominant pathogen in patients with cystic fibrosis (CF). To study the possibility of preventing lung inflammation and decreasing the progression of the infection by vaccination, we have developed a rat model of chronic P. aeruginosa lung infection. Rats were immunized with P. aeruginosa whole-cell sonicates, O-polysaccharide toxin A conjugate, an alginate-toxin A conjugate, or native alginate. Control animals received sterile saline or incomplete Freund's adjuvant (IFA). The macroscopic (mean score, 2.4 versus 2.7 to 3.2) (P < 0.05) and microscopic (mean score, 2.0 versus 2.1 to 2.8) pathologic abnormalities were less severe in the control rats injected with sterile saline than in the immunized rats and the IFA group. The more severe lung abnormalities observed in immunized rats could be due to the result of immune complex-mediated lung tissue damage. The histopathologic results in the saline control rats were characterized by acute inflammation dominated by numerous polymorphonuclear leukocytes surrounding the alginate beads (microcolonies), as in CF patients. In contrast, the inflammatory response in the IFA group and in the immunized rats had changed from an acute-type inflammation to a chronic-type inflammation dominated by mononuclear leukocytes and scattered granulomas. Cross-reacting antibodies were induced by the two alginate vaccines, and most immunized animals developed a significant (P < 0.001) antibody titer elevation (in enzyme-linked immunosorbent assay) of the immunoglobulin M (IgM), IgG, and IgA classes against the homologous antigens. The bacterial clearance was significantly (P < 0.05) more efficient in most immunized rats than in the control rats given sterile saline. The present study shows that none of the vaccines could completely prevent chronic lung inflammation 4 weeks after challenge. However, the changed pathologic condition in immunized rats to a chronic-type inflammation might be of great benefit in future management of CF patients since the developing lung tissue damage has been shown to be caused by polymorphonuclear leukocyte-released elastase.

Full text

PDF
3146

Images in this article

3152Image
on p.3152

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ames P., DesJardins D., Pier G. B. Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun. 1985 Aug;49(2):281–285. doi: 10.1128/iai.49.2.281-285.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baltimore R. S., Christie C. D., Smith G. J. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis. 1989 Dec;140(6):1650–1661. doi: 10.1164/ajrccm/140.6.1650. [DOI] [PubMed] [Google Scholar]
  3. Boyd R. L., Ramphal R., Rice R., Mangos J. A. Chronic colonization of rat airways with Pseudomonas aeruginosa. Infect Immun. 1983 Mar;39(3):1403–1410. doi: 10.1128/iai.39.3.1403-1410.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruderer U., Cryz S. J., Jr, Schaad U. B., Deusinger M., Que J. U., Lang A. B. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. J Infect Dis. 1992 Aug;166(2):344–349. doi: 10.1093/infdis/166.2.344. [DOI] [PubMed] [Google Scholar]
  5. Bryan L. E., Kureishi A., Rabin H. R. Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay. J Clin Microbiol. 1983 Aug;18(2):276–282. doi: 10.1128/jcm.18.2.276-282.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Buhles W. C., Jr, Shifrine M. Adjuvant protection against bacterial infection in granulocytopenic mice. J Infect Dis. 1977 Jul;136(1):90–95. doi: 10.1093/infdis/136.1.90. [DOI] [PubMed] [Google Scholar]
  7. Cash H. A., Woods D. E., McCullough B., Johanson W. G., Jr, Bass J. A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis. 1979 Mar;119(3):453–459. doi: 10.1164/arrd.1979.119.3.453. [DOI] [PubMed] [Google Scholar]
  8. Cochrane D. M., Brown M. R., Anwar H., Weller P. H., Lam K., Costerton J. W. Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection. J Med Microbiol. 1988 Dec;27(4):255–261. doi: 10.1099/00222615-27-4-255. [DOI] [PubMed] [Google Scholar]
  9. Cross A. S., Sadoff J. C., Iglewski B. H., Sokol P. A. Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis. 1980 Oct;142(4):538–546. doi: 10.1093/infdis/142.4.538. [DOI] [PubMed] [Google Scholar]
  10. Cryz S. J., Jr, Fürer E., Cross A. S., Wegmann A., Germanier R., Sadoff J. C. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest. 1987 Jul;80(1):51–56. doi: 10.1172/JCI113062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cryz S. J., Jr, Fürer E., Germanier R. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun. 1983 Mar;39(3):1072–1079. doi: 10.1128/iai.39.3.1072-1079.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cryz S. J., Jr, Fürer E., Que J. U. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun. 1991 Jan;59(1):45–50. doi: 10.1128/iai.59.1.45-50.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cryz S. J., Jr, Pitt T. L., Fürer E., Germanier R. Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect Immun. 1984 May;44(2):508–513. doi: 10.1128/iai.44.2.508-513.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cryz S. J., Jr, Sadoff J. C., Cross A. S., Fürer E. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans. Antibiot Chemother (1971) 1989;42:177–183. doi: 10.1159/000417618. [DOI] [PubMed] [Google Scholar]
  15. Döring G., Dauner H. M. Clearance of Pseudomonas aeruginosa in different rat lung models. Am Rev Respir Dis. 1988 Nov;138(5):1249–1253. doi: 10.1164/ajrccm/138.5.1249. [DOI] [PubMed] [Google Scholar]
  16. Döring G., Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983 Oct;42(1):197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fierer J., Eckmann L., Kagnoff M. IL-8 secreted by epithelial cells invaded by bacteria. Infect Agents Dis. 1993 Aug;2(4):255–258. [PubMed] [Google Scholar]
  18. Fomsgaard A. Antibodies to lipopolysaccharides: some diagnostic and protective aspects. APMIS Suppl. 1990;18:1–38. [PubMed] [Google Scholar]
  19. Fomsgaard A., Shand G. H., Freudenberg M. A., Galanos C., Conrad R. S., Kronborg G., Høiby N. Antibodies from chronically infected cystic fibrosis patients react with lipopolysaccharides extracted by new micromethods from all serotypes of Pseudomonas aeruginosa. APMIS. 1993 Feb;101(2):101–112. doi: 10.1111/j.1699-0463.1993.tb00088.x. [DOI] [PubMed] [Google Scholar]
  20. Fyfe J. A., Govan J. R. Alginate synthesis in mucoid Pseudomonas aeruginosa: a chromosomal locus involved in control. J Gen Microbiol. 1980 Aug;119(2):443–450. doi: 10.1099/00221287-119-2-443. [DOI] [PubMed] [Google Scholar]
  21. Garner C. V., DesJardins D., Pier G. B. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun. 1990 Jun;58(6):1835–1842. doi: 10.1128/iai.58.6.1835-1842.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gilleland H. E., Gilleland L. B., Fowler M. R. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J Med Microbiol. 1993 Feb;38(2):79–86. doi: 10.1099/00222615-38-2-79. [DOI] [PubMed] [Google Scholar]
  23. Gilleland H. E., Jr, Gilleland L. B., Matthews-Greer J. M. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect Immun. 1988 May;56(5):1017–1022. doi: 10.1128/iai.56.5.1017-1022.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Goldstein W., Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis. 1986 Jul;134(1):49–56. doi: 10.1164/arrd.1986.134.1.49. [DOI] [PubMed] [Google Scholar]
  25. Govan J. R., Fyfe J. A. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother. 1978 May;4(3):233–240. doi: 10.1093/jac/4.3.233. [DOI] [PubMed] [Google Scholar]
  26. Govan J. R., Harris G. S. Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis. Microbiol Sci. 1986 Oct;3(10):302–308. [PubMed] [Google Scholar]
  27. Graham L. M., Vasil A., Vasil M. L., Voelkel N. F., Stenmark K. R. Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia. Am Rev Respir Dis. 1990 Jul;142(1):221–229. doi: 10.1164/ajrccm/142.1.221. [DOI] [PubMed] [Google Scholar]
  28. Iwata M., Sato A. Morphological and immunohistochemical studies of the lungs and bronchus-associated lymphoid tissue in a rat model of chronic pulmonary infection with Pseudomonas aeruginosa. Infect Immun. 1991 Apr;59(4):1514–1520. doi: 10.1128/iai.59.4.1514-1520.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Johansen H. K., Espersen F., Pedersen S. S., Hougen H. P., Rygaard J., Høiby N. Chronic Pseudomonas aeruginosa lung infection in normal and athymic rats. APMIS. 1993 Mar;101(3):207–225. [PubMed] [Google Scholar]
  30. Johansen H. K., Høiby N. Local IgA and IgG response to intratracheal immunization with Pseudomonas aeruginosa antigens. APMIS. 1992 Jan;100(1):87–90. [PubMed] [Google Scholar]
  31. Johansen H. K., Høiby N., Pedersen S. S. Experimental immunization with Pseudomonas aeruginosa alginate induces IgA and IgG antibody responses. APMIS. 1991 Dec;99(12):1061–1068. [PubMed] [Google Scholar]
  32. Kharazmi A., Schiøtz P. O., Høiby N., Baek L., Döring G. Demonstration of neutrophil chemotactic activity in the sputum of cystic fibrosis patients with Pseudomonas aeruginosa infection. Eur J Clin Invest. 1986 Apr;16(2):143–148. doi: 10.1111/j.1365-2362.1986.tb01321.x. [DOI] [PubMed] [Google Scholar]
  33. Klinger J. D., Cash H. A., Wood R. E., Miler J. J. Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats. Infect Immun. 1983 Mar;39(3):1377–1384. doi: 10.1128/iai.39.3.1377-1384.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Konstan M. W., Vargo K. M., Davis P. B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186–192. doi: 10.1164/ajrccm/141.1.186. [DOI] [PubMed] [Google Scholar]
  35. Kronborg G., Fomsgaard A., Galanos C., Freudenberg M. A., Høiby N. Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients. J Clin Microbiol. 1992 Jul;30(7):1848–1855. doi: 10.1128/jcm.30.7.1848-1855.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  37. Lam J., Chan R., Lam K., Costerton J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun. 1980 May;28(2):546–556. doi: 10.1128/iai.28.2.546-556.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Langford D. T., Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child. 1984 Dec;59(12):1131–1134. doi: 10.1136/adc.59.12.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Mai G. T., Seow W. K., Pier G. B., McCormack J. G., Thong Y. H. Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. Infect Immun. 1993 Feb;61(2):559–564. doi: 10.1128/iai.61.2.559-564.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. McElvaney N. G., Hubbard R. C., Birrer P., Chernick M. S., Caplan D. B., Frank M. M., Crystal R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394. doi: 10.1016/0140-6736(91)91167-s. [DOI] [PubMed] [Google Scholar]
  41. McElvaney N. G., Nakamura H., Birrer P., Hébert C. A., Wong W. L., Alphonso M., Baker J. B., Catalano M. A., Crystal R. G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296–1301. doi: 10.1172/JCI115994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  43. Moss R. B., Hsu Y. P., Lewiston N. J., Curd J. G., Milgrom H., Hart S., Dyer B., Larrick J. W. Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis. 1986 Apr;133(4):648–652. doi: 10.1164/arrd.1986.133.4.648. [DOI] [PubMed] [Google Scholar]
  44. Nacucchio M. C., Cerquetti M. C., Meiss R. P., Sordelli D. O. Short communication. Role of agar beads in the pathogenicity of Pseudomonas aeruginosa in the rat respiratory tract. Pediatr Res. 1984 Mar;18(3):295–296. doi: 10.1203/00006450-198403000-00018. [DOI] [PubMed] [Google Scholar]
  45. Pedersen S. S., Espersen F., Høiby N., Shand G. H. Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 1989 Apr;27(4):691–699. doi: 10.1128/jcm.27.4.691-699.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Pedersen S. S., Kharazmi A., Espersen F., Høiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun. 1990 Oct;58(10):3363–3368. doi: 10.1128/iai.58.10.3363-3368.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pedersen S. S. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS Suppl. 1992;28:1–79. [PubMed] [Google Scholar]
  48. Pedersen S. S., Shand G. H., Hansen B. L., Hansen G. N. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS. 1990 Mar;98(3):203–211. [PubMed] [Google Scholar]
  49. Pennington J. E., Hickey W. F., Blackwood L. L., Arnaut M. A. Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest. 1981 Nov;68(5):1140–1148. doi: 10.1172/JCI110358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pier G. B., Bennett S. E. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide. J Clin Invest. 1986 Feb;77(2):491–495. doi: 10.1172/JCI112328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pier G. B., Saunders J. M., Ames P., Edwards M. S., Auerbach H., Goldfarb J., Speert D. P., Hurwitch S. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med. 1987 Sep 24;317(13):793–798. doi: 10.1056/NEJM198709243171303. [DOI] [PubMed] [Google Scholar]
  52. Pier G. B., Small G. J., Warren H. B. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science. 1990 Aug 3;249(4968):537–540. doi: 10.1126/science.2116663. [DOI] [PubMed] [Google Scholar]
  53. Pollack M., Young L. S. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979 Feb;63(2):276–286. doi: 10.1172/JCI109300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Roberts P., Jeffery P. K., Mitchell T. J., Andrew P. W., Boulnois G. J., Feldman C., Cole P. J., Wilson R. Effect of immunization with Freund's adjuvant and pneumolysin on histologic features of pneumococcal infection in the rat lung in vivo. Infect Immun. 1992 Nov;60(11):4969–4972. doi: 10.1128/iai.60.11.4969-4972.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Schaad U. B., Lang A. B., Wedgwood J., Buehlamnn U., Fuerer E. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity. Pediatr Res. 1990 May;27(5):508–513. doi: 10.1203/00006450-199005000-00019. [DOI] [PubMed] [Google Scholar]
  56. Schaad U. B., Lang A. B., Wedgwood J., Ruedeberg A., Que J. U., Fürer E., Cryz S. J., Jr Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet. 1991 Nov 16;338(8777):1236–1237. doi: 10.1016/0140-6736(91)92103-9. [DOI] [PubMed] [Google Scholar]
  57. Stiver H. G., Zachidniak K., Speert D. P. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med. 1988 Aug;11(4):247–252. [PubMed] [Google Scholar]
  58. Suter S., Schaad U. B., Roux L., Nydegger U. E., Waldvogel F. A. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis. 1984 Apr;149(4):523–531. doi: 10.1093/infdis/149.4.523. [DOI] [PubMed] [Google Scholar]
  59. Tosi M. F., Zakem H., Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 1990 Jul;86(1):300–308. doi: 10.1172/JCI114699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Woods D. E., Bryan L. E. Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals. J Infect Dis. 1985 Apr;151(4):581–588. doi: 10.1093/infdis/151.4.581. [DOI] [PubMed] [Google Scholar]
  61. Woods D. E., Cryz S. J., Friedman R. L., Iglewski B. H. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun. 1982 Jun;36(3):1223–1228. doi: 10.1128/iai.36.3.1223-1228.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES